The board of directors of Tongfang Kontafarma Holdings Limited announced that Mr. Zhang Yi has tendered his resignation as a non-executive Director and a member of the share dealing committee of the Board with effect from 23 January 2018 in order to pursue other personal and business commitments. The Board announced that with effect from 23 January 2018, Mr. Jiang Chaowen, the chief executive officer of the Company, has been appointed as an executive Director and a member of each of the executive committee of the Board and the Share Dealing Committee. Mr. Jiang, aged 52, joined the Group in July 2016, is currently the president of (Tongfang Pharmaceutical Group Co., Ltd) (formerly known as (Beijing Ziguang Pharmaceutical Co. Ltd.)) and the chairman of (SPF (Beijing) Biotechnology Co. Ltd.), (Chongqing Kangle Pharmaceutical Co. Ltd.), (Shaanxi Unisplendour Life Care Pharmaceutical Co. Ltd.) and (Tibet Linzhi Medical Pharmaceutical Co. Ltd.), all of which are the subsidiaries of the Company.